VTVT - VTv Therapeutics' Elevage study suggests comparability to diabetes subgroup of Phase 3 STEADFAST study

VTv Therapeutics (VTVT) reports baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimer’s disease ((AD)) in people with type 2 diabetes.The data demonstrate that the patients enrolled in Elevage (n=43) have similar baseline characteristics to those in the STEADFAST A-study type 2 diabetes (T2D) subgroup (n=47).As the company reported in October 2018, data from this subgroup demonstrated nominally significant differences favoring azeliragon compared with placebo on the ADAS-cog11, an instrument used to evaluate cognition.The goal of the Elevage study is to confirm the results of these retrospective analyses in a 6-month Phase 2 study prior to initiating a Phase 3 study. The company expects to report topline safety and efficacy data from Part 1 of the Elevage study in December 2020, earlier than previously anticipated.The Elevage data are being presented at the 13th Clinical Trials on Alzheimer’s Disease ((CTAD))

For further details see:

VTv Therapeutics' Elevage study suggests comparability to diabetes subgroup of Phase 3 STEADFAST study